Ventus Therapeutics
- Founded: 2019
- Location: Waltham, MA
- Employee range: 11 - 50
- Clinical stage: Clin0
- Therapy area: Immunology, Rheumatology
- Drug types: IMM, RHU, DRM, NEU, GI, HEP, NPH, CVV
- Lead product: VENT-03
- Product link: https://www.ventustx.com/pipeline/pipeline/
- Funding: $140M C Feb 2022; $100M Apr 2021; $60M A May 2020
- Investors: Versant Ventures
ventustx.com linkedin.com job board
Short description:
Small Molecules targeting proteins in the inflammasome and nucleic acid sensing signaling pathways
Drug notes:
VENT-02 Clin1 neuro; VENT-01 Clin0 renal, cardiovascular, hepatic; VENT-05 RD undisclosed; VENT-04 RD various
Long description:
Ventus Therapeutics uses structural biology and computational chemistry tools to address a wide range of diseases, including immunology, inflammatory, and neurological disorders. Their drug discovery platform models all protein conformations to identify druggable pockets in order to create a “blueprint” for developing small molecule therapeutics. Through their platform, Ventus can virtually screen libraries of compounds to identify molecules that resemble the “blueprint”and then optimize them for improved efficacy. They aim to address current limitations in industry. Their expertise in protein engineering, structure determination, and expression enables them to confront previously challenging targets like the inflammasome and nucleic acid sensing pathways.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com